Alexion Pharmaceuticals Inc. (ALXN)

109.43
NASDAQ : Health Technology
Prev Close 112.43
Day Low/High 108.86 / 112.24
52 Wk Low/High 102.10 / 140.77
Avg Volume 1.59M
Exchange NASDAQ
Shares Outstanding 223.10M
Market Cap 26.10B
EPS 2.00
P/E Ratio 24.55
Div & Yield N.A. (N.A)

Latest News

Alexion To Present At Credit Suisse's 27th Annual Healthcare Conference

Alexion To Present At Credit Suisse's 27th Annual Healthcare Conference

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at Credit Suisse's 27 th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 10:00 a.

Alexion Completes Acquisition Of Syntimmune

Alexion Completes Acquisition Of Syntimmune

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the previously announced acquisition of Syntimmune has been successfully completed.

Alexion Announces Upcoming Data Presentations At American Society Of Hematology Annual Meeting

Alexion Announces Upcoming Data Presentations At American Society Of Hematology Annual Meeting

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that nine abstracts from its complement research and development program have been accepted for presentation at the American Society of Hematology (ASH) Annual Meeting in San Diego, December 1 to...

Alexion Reports Third Quarter 2018 Results

Alexion Reports Third Quarter 2018 Results

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the third quarter of 2018.

Alexion And Dicerna Announce Collaboration To Discover And Develop RNAi Therapies For Complement-Mediated Diseases

Alexion And Dicerna Announce Collaboration To Discover And Develop RNAi Therapies For Complement-Mediated Diseases

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Dicerna Pharmaceuticals, Inc.

Alexion To Report Third Quarter 2018 Results On Wednesday, October 24, 2018

Alexion To Report Third Quarter 2018 Results On Wednesday, October 24, 2018

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2018 before the US financial markets open on October 24, 2018.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Alexion To Acquire Syntimmune

Alexion To Acquire Syntimmune

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Syntimmune today announced that they have entered into a definitive agreement for Alexion to acquire Syntimmune, a clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal...

Alexion To Present At The Leerink Partners Roundtable Series: Rare Disease & Oncology

Alexion To Present At The Leerink Partners Roundtable Series: Rare Disease & Oncology

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New York, NY on Tuesday, October 2, 2018 at 10 a.

Another Day of Rotation, but of a Different Sort

Another Day of Rotation, but of a Different Sort

Big-cap FAANG names and Apple, in particular, were the beneficiaries.

Alexion Announces Successful Phase 3 PREVENT Study Of Soliris® (Eculizumab) In Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Alexion Announces Successful Phase 3 PREVENT Study Of Soliris® (Eculizumab) In Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced positive topline results from the Phase 3 PREVENT study of Soliris ® (eculizumab) in patients with anti-aquaporin-4 (AQP4) auto antibody-positive neuromyelitis optica spectrum disorder (NMOSD).

The New #45 Most Shorted Nasdaq 100 Component: Alexion Pharmaceuticals

The New #45 Most Shorted Nasdaq 100 Component: Alexion Pharmaceuticals

The most recent short interest data has been released for the 08/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Alexion To Present At Morgan Stanley's 16th Annual Global Healthcare Conference

Alexion To Present At Morgan Stanley's 16th Annual Global Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Morgan Stanley's 16 th Annual Global Healthcare Conference in New York, NY on Friday, September 14, 2018 at 11:05 a.

Alexion To Present At Citi's 13th Annual Biotech Conference

Alexion To Present At Citi's 13th Annual Biotech Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Citi's 13 th Annual Biotech Conference in Boston, MA on Thursday, September 6, 2018 at 8:15 a.

FDA Accepts Priority Review Of ALXN1210 As A Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The US

FDA Accepts Priority Review Of ALXN1210 As A Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The US

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.

Alexion Reports Second Quarter 2018 Results

Alexion Reports Second Quarter 2018 Results

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the second quarter of 2018.

Alexion To Report Second Quarter 2018 Results On Thursday, July 26, 2018

Alexion To Report Second Quarter 2018 Results On Thursday, July 26, 2018

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the second quarter ended June 30, 2018 before the US financial markets open on July 26, 2018.

Alexion Submits Application For Approval Of ALXN1210 As A Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The European Union (EU)

Alexion Submits Application For Approval Of ALXN1210 As A Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The European Union (EU)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for ALXN1210, the Company's investigational long-acting C5 complement inhibitor, for the treatment...

5 Stocks That Are Screaming Buys Right Now

5 Stocks That Are Screaming Buys Right Now

Stay active and selective: These are the five best stocks to invest in right now

Alexion Submits Application For Priority Review And Approval Of ALXN1210 As A Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The U.S.

Alexion Submits Application For Priority Review And Approval Of ALXN1210 As A Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The U.S.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the submission of a Biologics License Application (BLA) to the U.

Alexion Announces Selection Of Positive Phase 3 Clinical Data For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) For Late-Breaking Oral Presentation At Annual Conference Of The European Hematology Association (EHA)

Alexion Announces Selection Of Positive Phase 3 Clinical Data For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) For Late-Breaking Oral Presentation At Annual Conference Of The European Hematology Association (EHA)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that positive results from one of the two large Phase 3 studies of ALXN1210, the Company's investigational long-acting C5 complement inhibitor, in patients with paroxysmal nocturnal...

Alexion Pharmaceuticals Becomes #37 Most Shorted Nasdaq 100 Component, Replacing CSX

Alexion Pharmaceuticals Becomes #37 Most Shorted Nasdaq 100 Component, Replacing CSX

The most recent short interest data has been released for the 05/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Alexion And Complement Pharma Announce Partnership To Co-Develop Pre-Clinical Complement Inhibitor For Neurodegenerative Disorders

Alexion And Complement Pharma Announce Partnership To Co-Develop Pre-Clinical Complement Inhibitor For Neurodegenerative Disorders

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Complement Pharma today announced a partnership to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders.

Alexion To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

Alexion To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 12, 2018 at 11:20 a.

Alexion Pharmaceuticals Becomes #48 Most Shorted Nasdaq 100 Component, Replacing Dollar Tree

Alexion Pharmaceuticals Becomes #48 Most Shorted Nasdaq 100 Component, Replacing Dollar Tree

The most recent short interest data has been released for the 05/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Alexion Offer For Wilson Therapeutics Accepted

Alexion Offer For Wilson Therapeutics Accepted

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its offer, through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by shareholders representing 97.

Alexion To Present At The Bank Of America Merrill Lynch 2018 Health Care Conference

Alexion To Present At The Bank Of America Merrill Lynch 2018 Health Care Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Wednesday, May 16, 2018 at 2:20 p.

Alexion Reports First Quarter 2018 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study

Alexion Reports First Quarter 2018 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the first quarter of 2018.

TheStreet Quant Rating: C+ (Hold)